UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e004024

2022

Volltextzugriff (PDF)

Management of toxicities of immune checkpoint inhibitors

Cancer treatment reviews, 2016-03, Vol.44, p.51-60

2016

Volltextzugriff (PDF)

Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Journal of immunotherapy (1997), 2016-11, Vol.39 (9), p.379-382

2016

Volltextzugriff (PDF)

Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma

ESMO open, 2020-07, Vol.5 (4), p.e000585, Article e000585

2020

Volltextzugriff (PDF)

Mycophenolate mofetil as second line treatment in autoimmune hepatitis – A retrospective single center analysis

Journal of translational autoimmunity (Online), 2022-01, Vol.5, p.100172-100172, Article 100172

2022

Volltextzugriff (PDF)

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.50-50, Article 50

2019

Volltextzugriff (PDF)

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

Journal for immunotherapy of cancer, 2021-05, Vol.9 (5), p.e002350

2021

Volltextzugriff (PDF)

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

Lung cancer (Amsterdam, Netherlands), 2017-09, Vol.111, p.176-181

2017

Volltextzugriff (PDF)

Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project

ESMO open, 2019, Vol.4 (6), p.e000596-e000596, Article e000596

2019

Volltextzugriff (PDF)

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors

European journal of cancer (1990), 2019-01, Vol.107, p.8-14

2019

Volltextzugriff (PDF)

Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)

Cancer Immunology, Immunotherapy, 2018-12, Vol.67 (12), p.1825-1832

2018

Volltextzugriff (PDF)

Prognostic score for patients with advanced melanoma treated with ipilimumab

European journal of cancer (1990), 2015-12, Vol.51 (18), p.2785-2791

2015

Volltextzugriff (PDF)

EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report

Case reports in oncology, 2013-06, Vol.6 (2), p.316-319

2013

Volltextzugriff (PDF)

BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors

Journal of the American Academy of Dermatology, 2020-04, Vol.82 (4), p.854-861

2020

Volltextzugriff (PDF)

BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma

Expert opinion on pharmacotherapy, 2015-06, Vol.16 (9), p.1285-1297

2015

Volltextzugriff (PDF)

Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer

Oncoimmunology, 2016-01, Vol.5 (11), p.e1231292-e1231292

2016

Volltextzugriff (PDF)

Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease

Cancer Immunology, Immunotherapy, 2018-01, Vol.67 (1), p.39-45

2018

Volltextzugriff (PDF)

Accelerated Course of Alveolar Echinococcosis After Treatment With Steroids in a Patient With Autoimmune Encephalitis

Curēus (Palo Alto, CA), 2021-10

2021

Volltextzugriff (PDF)

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

Journal of immunotherapy (1997), 2019-04, Vol.42 (3), p.89-93

2019

Volltextzugriff (PDF)

Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade

American journal of respiratory and critical care medicine, 2024-10, Vol.210 (7), p.919-930

2024

Volltextzugriff (PDF)

Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients

Journal of cancer research and clinical oncology, 2022-03, Vol.148 (3), p.647-656

2022

Volltextzugriff (PDF)

First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor

Journal of cancer research and therapeutics, 2021-01, Vol.17 (1), p.276-278

2021

Volltextzugriff (PDF)

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors

Med (New York, N.Y. : Online), 2023-02, Vol.4 (2), p.113-129.e7

2023

Volltextzugriff (PDF)

Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients

Cancer Immunology, Immunotherapy, 2021-02, Vol.70 (2), p.563-568

2021

Volltextzugriff (PDF)

1 – 25 von 155

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(118)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(140)
Deutsch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(92)
Life Sciences & Biomedicine
(61)
Humans
(41)
Female
(28)
Male
(28)
Oncology
(27)
Middle Aged
(22)
Technology
(22)
Immunology
(18)
Aged
(16)
Immunotherapy
(15)
Adult
(14)
Schweiz
(14)
Science & Technology - Other Topics
(13)
Melanoma
(12)
Melanoma - Drug Therapy
(12)
Patients
(12)
Engineering
(11)
Metastasis
(10)
Prospective Studies
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

Management of toxicities of immune checkpoint inhibitors

Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma

Mycophenolate mofetil as second line treatment in autoimmune hepatitis – A retrospective single center analysis

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors

Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)

Prognostic score for patients with advanced melanoma treated with ipilimumab

EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report

BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer

BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma

Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer

Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease

Accelerated Course of Alveolar Echinococcosis After Treatment With Steroids in a Patient With Autoimmune Encephalitis

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade

Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients

First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors

Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients

Suchergebnisse filtern